8Pastor A, Menendez R, Cremades MJ, et al. Diagnostic value of SCC, CEA and CYFRA21-1 in lung cancer: a Bayesian analysis. Eur Respir J, 1997, 10:603-609.
6Sun SS, Hsieh JF, Tsai SC, et al. Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma[J ]. American Journal of Clinical Oncology, 2000, 23(3): 241.
7Buccheri G, Torchio P,Ferrigno D. Cliniacl equivalence of two cytokeratin markers in non-small cell lung cancer:A study of tissue polypeptide antigen and cytokeratin 19 fragments[J]. Chest, 2003, 124(2): 622-626.
8Ando S, Kimura H, Iwai N, et al. Optimal combination of seven tumour markers in prediction of advanced stageat first examination of patients with non-small cell lung cancer[J]. Anticancer Res, 2001, 21(4B): 3085-3092.
9Karnak D, Ulubay G, Kayacan O, et al. Evaluation of cyfra21-1: a potential tumor marker for non-small cel lung carcinomas[J]. Lung, 2001, 175:57-65.
4Sung H J,Cho J Y.Biomarkers for the lung cancer diagnosis and their advances in proteomics[J].BMB Rep,2008,41(9):615-625.
5Zweig H M,Campbell G.Receive-operating characteristic plots:a fundamental evaluation tool in clinical medicine[J].Clin Chem,1993,39(4):561.
6Rajeswaran A,Trojan A,Burnand B,et al.Efficacy and side effects of cisplatin and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma:a systematic review of randomized controlled trials[J].Lung Cancer,2008,59(1):1-11.
7Govindan R,Morgensztern D,Kommor MD,et al.Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer[J].J Thorac Oncol,2011,6(4):790-795.
8Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346:92-98.
9Trillet-Lenoir V,Freyer G,Kaemmerlen P,et al.Assessment of tumour response to chemotherapy for metastatic colorectal cancer:accuracy of the RECIST criteria[J].Br J Radiol,2002,75(899):903-908.
10Chou WC,Huang SF,Yeh KY,et al.Different responses to gefitinib in lung adenocarcinoma coexpressing mutant and wild-type epidermal growth factor receptor genes[J].Jpn J Clin Oncol,2006,36:523-526.
